Recently, a groundbreaking study introduced an experimental gene-editing drug capable of significantly reducing LDL cholesterol levels. This could be a monumental step in preventing heart disease.
The preliminary research involved administering a single infusion of the gene-editing treatment. Results showed a dramatic decrease in cholesterol, potentially permanent, in those who received it.
Researchers are optimistic about the potential impact of this treatment, particularly given that cardiovascular disease is a major health challenge, resulting in nearly 800,000 deaths annually in the U.S.
Dr. John H. P. Alexander, a cardiologist at Duke University, commented on the study’s implications, noting that a curative therapy might transform current practices in treating heart disease.
The interim report published in The New England Journal of Medicine covered 35 patients. These participants were identified with genetically high LDL levels or existing heart disease.
Among the patients, those treated with the highest dose saw LDL levels fall by up to 62%. This reduction persisted in a subgroup monitored for 18 months post-treatment.
While the journal rarely publishes initial findings, the promising results and innovative approach to treating the leading cause of death in the U.S. justified an exception, said Dr. Eric Rubin, editor in chief.
Looking ahead, researchers plan an expanded study involving 200 patients to confirm efficacy and safety.
First Ebola Case Confirmed in France as Health Officials Track Contacts 
Cancer Death Rates Drop: Challenges in Addressing Disparities 
A Study on COVID-19 Vaccine Effectiveness Published 
Efforts to Combat Hospice Fraud and Protect Patient Care 
Study on Vaccine’s Impact on Emergency Visits and Hospitalizations 
Protein Tubulin Offers Hope in Combatting Alzheimer’s and Parkinson’s Disease